The Role of Biologics in the Treatment of Chronic Rhinosinusitis Nora HaloobKaterina KaramaliClaire Hopkins Review Article 15 June 2023 Pages: 477 - 487
Base Editing and Prime Editing: Potential Therapeutic Options for Rare and Common Diseases Lauren C. TestaKiran Musunuru Review Article 14 June 2023 Pages: 453 - 462
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria Bernardo Cavallazzi SeboldJunjie LiTianfang Wang Review Article Open access 10 June 2023 Pages: 607 - 623
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart Akshay G. MishraRutuja B. DeshmaneArchana R. Krishnan Original Research Article 07 June 2023 Pages: 709 - 719
Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults Chen LiHaiyan LiuYi Fang Original Research Article 06 June 2023 Pages: 721 - 735
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database Orhon PaulineMarion RobertCharles Khouri Original Research Article 06 June 2023 Pages: 699 - 707
Antibody–Drug Conjugates in the Treatment of Urothelial Cancer Avani M. SinghJose A. Guevara-PatinoRohit K. Jain Review Article 31 May 2023 Pages: 505 - 520
Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma Saïf Eddine ZaidiEliese MoelkerMustafa Khasraw Review Article 31 May 2023 Pages: 489 - 503
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022 Ryosuke KuribayashiAyuki NakanoFutaba Honda Leading Article 25 May 2023 Pages: 443 - 451
Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study Steven R. FeldmanRichard KayFausto Berti Original Research Article Open access 19 May 2023 Pages: 551 - 567
Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus Mingshu HuangWeixing ChenBo Jia Review Article 13 May 2023 Pages: 331 - 352
CAR-T Cells and the Kidney: Insights from the WHO Safety Database Alexandre O. GérardDiane MerinoMilou-Daniel Drici Original Research Article Open access 11 May 2023 Pages: 521 - 530
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy Francesco CiccimarraNicoletta LuxiGianluca Trifirò Original Research Article Open access 06 May 2023 Pages: 675 - 684
Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus Charl VerweyShabir A. Madhi Review Article Open access 25 April 2023 Pages: 295 - 309
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery Amir Hossein MohammadiZeinab GhazvinianKaveh Baghaei Review Article 24 April 2023 Pages: 353 - 374
Lupus Nephritis: New and Emerging Biologic and Targeted Therapies Ajinath KaleMaciej LechAnil Bhanudas Gaikwad Review Article 24 April 2023 Pages: 463 - 475
Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method Hyunsoo KimEunkyoung HongTaekyung Yoo Original Research Article Open access 15 April 2023 Pages: 569 - 581
Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome) Valentina D. GusarovaMaxim A. SmolovRahim R. Shukurov Original Research Article 04 April 2023 Pages: 375 - 395
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor Jette A. van LintNaomi T. JessurunBart J. F. van den Bemt Original Research Article Open access 03 April 2023 Pages: 541 - 550
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans Tianzhou YuShihan JinJakub P. Hlávka Original Research Article Open access 01 April 2023 Pages: 531 - 540
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis Kuan PengJoseph E. BlaisXue Li Original Research Article Open access 23 March 2023 Pages: 409 - 420
Correction to: Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study Douglas J. RupertAlyssa M. JordanR. Craig Lefebvre Correction 07 March 2023 Pages: 441 - 441
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial Justin StebbingYauheni BaranauSunghyun Kim Short Communication Open access 07 March 2023 Pages: 433 - 440
Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System Hugo JourdainLéa HoisnardMahmoud Zureik Original Research Article Open access 06 March 2023 Pages: 397 - 407
Targeting IL-36 in Inflammatory Skin Diseases Ryo FukauraMasashi Akiyama Leading Article 03 March 2023 Pages: 279 - 293
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer Motahareh ArjomandnejadIshani DasguptaAllison M. Keeler Review Article Open access 02 March 2023 Pages: 311 - 329
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing Taihang ShaoMingye ZhaoWenxi Tang Original Research Article 25 February 2023 Pages: 421 - 432
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial Huiping LiYan HuangLi Zhang Original Research Article Open access 21 February 2023 Pages: 259 - 269
Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia László LorenzoviciLászló SzilberhornMarcell Csanádi Systematic Review Open access 16 February 2023 Pages: 219 - 233
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis Adam IoannouMarianna FontanaJulian D. Gillmore Review Article Open access 16 February 2023 Pages: 127 - 142
Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study Sun-Kyung LeeKichul ShinHyoun-Ah Kim Original Research Article 09 February 2023 Pages: 247 - 257
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis HyeJung NaSun-Hong KwonEui-Kyung Lee Systematic Review 02 February 2023 Pages: 205 - 218
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context Maximilian RuschigAndrea L. J. Marschall Review Article Open access 02 February 2023 Pages: 181 - 203
Consistency of Product Quality for SB5, an Adalimumab Biosimilar JongAh Joanne LeeNayoung LeeIlkoo Kim Original Research Article Open access 31 January 2023 Pages: 271 - 277
Copies of Biological Medicines: Similar But Not the Same? Pekka Kurki Commentary Open access 30 January 2023 Pages: 123 - 126
Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines Bingming OuYing YangMinyu Zhang Review Article 06 January 2023 Pages: 143 - 180
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities Yuxiong JiangYoudong ChenYuling Shi Review Article Open access 02 January 2023 Pages: 35 - 55
Malaysian Hospital Pharmacists’ Perspectives and Their Role in Promoting Biosimilar Prescribing: A Nationwide Survey Noraisyah Mohd SaniZoriah AzizAdeeba Kamarulzaman Original Research Article 26 December 2022 Pages: 109 - 120
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy Dafne Müller Review Article Open access 26 December 2022 Pages: 21 - 33
Current Developments in the Preclinical and Clinical use of Natural Killer T cells Christina KratzmeierSasha SinghTonya J. Webb Review Article 16 December 2022 Pages: 57 - 71
Complement Inhibition in Kidney Transplantation: Where Are We Now? Eva VonbrunnMaike Büttner-HeroldChristoph Daniel Current Opinion Open access 13 December 2022 Pages: 5 - 19
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries Kevin KleinMümün GencogluPieter Stolk Original Research Article Open access 06 December 2022 Pages: 235 - 245
Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations Kenta HarayaTatsuhiko Tachibana Original Research Article Open access 30 November 2022 Pages: 99 - 108
Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial Min WuXiaojiao LiYanhua Ding Original Research Article 22 November 2022 Pages: 89 - 98
Correction to: First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data Maxime BoussageonAurélie SwalduzOlivier Bylicki Correction 19 November 2022 Pages: 121 - 121
Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®) Amandine DernoncourtSophie LiabeufBenjamin Batteux Original Research Article Open access 19 November 2022 Pages: 73 - 87
Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region Miguel AlpalhãoJoana DuartePaulo Filipe Original Research Article 05 November 2022 Pages: 781 - 789
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association Claudia Di MuzioPaola CiprianiPiero Ruscitti Leading Article Open access 02 November 2022 Pages: 673 - 685
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine Johanna Elin GehinGuro Løvik GollSilje Watterdal Syversen Review Article Open access 31 October 2022 Pages: 731 - 748